TY - JOUR
KW - adoptive cell therapy
KW - Cancer vaccine
KW - Cytokine therapy
KW - Humans
KW - Immune checkpoint inhibitor
KW - Immunotherapy
KW - in vitro models
KW - Lab-On-A-Chip Devices
KW - microphysiological systems
KW - Neoplasms
KW - Oncolytic viruses
KW - Tumor-on-chip
AU - Tengku Ibrahim Maulana
AU - Elena Kromidas
AU - Lars Wallstabe
AU - Madalena Cipriano
AU - Miriam Alb
AU - Cécile Zaupa
AU - Michael Hudecek
AU - Birgit Fogal
AU - Peter Loskill
AB - The advances in cancer immunotherapy come with several obstacles, limiting its widespread use and benefits so far only to a small subset of patients. One of the underlying challenges remains to be the lack of representative nonclinical models that translate to human immunity and are able to predict clinical efficacy and safety outcomes. In recent years, immunocompetent Cancer-on-Chip models emerge as an alternative human-based platform that enables the integration and manipulation of complex tumor microenvironment. In this review, we discuss novel opportunities offered by Cancer-on-Chip models to advance (mechanistic) immuno-oncology research, ranging from design flexibility to multimodal analysis approaches. We then exemplify their (potential) applications for the research and development of adoptive cell therapy, immune checkpoint therapy, cytokine therapy, oncolytic virus, and cancer vaccines.
BT - Advanced Drug Delivery Reviews
DA - 2021-06
DO - 10.1016/j.addr.2021.03.015
LA - eng
N2 - The advances in cancer immunotherapy come with several obstacles, limiting its widespread use and benefits so far only to a small subset of patients. One of the underlying challenges remains to be the lack of representative nonclinical models that translate to human immunity and are able to predict clinical efficacy and safety outcomes. In recent years, immunocompetent Cancer-on-Chip models emerge as an alternative human-based platform that enables the integration and manipulation of complex tumor microenvironment. In this review, we discuss novel opportunities offered by Cancer-on-Chip models to advance (mechanistic) immuno-oncology research, ranging from design flexibility to multimodal analysis approaches. We then exemplify their (potential) applications for the research and development of adoptive cell therapy, immune checkpoint therapy, cytokine therapy, oncolytic virus, and cancer vaccines.
PY - 2021
SP - 281
EP - 305
T2 - Advanced Drug Delivery Reviews
TI - Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
VL - 173
SN - 1872-8294
ER -